Skip to search formSkip to main contentSkip to account menu

brivanib

Known as: (R)-1-(4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol 
A pyrrolotriazine-based compound and an inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2) with potential antineoplastic activity… 
National Institutes of Health

Related topics

Related topics

12 relations

Broader (2)

AlanineTriazines

Narrower (3)

BMS 540215BMS 582664brivanib alaninate
Inhibition of Cell ProliferationNCIt Antineoplastic Agent TerminologyPositive Regulation of ApoptosisReceptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
The In�ammator�Microenvironment in �epatocellular Carcinoma : A Pivotal Role for Tumor-AssociatedMacrophages
Hepatocellular carcinoma (HCC) is one of the most common and aggressive human cancers worldwide. HCC is an example of in�ammation… 
Review
2015
Review
2015
Перспективы терапевтического воздействия на сигнальный путь FGFR
Fibroblast growth factors (FGFs) and their receptors (FGFRs) are involved in key cellular functions and cancerogenesis. Nowadays… 
2014
2014
thepatientsweresimilarensuredacorrectcomparisonbetweenthe targetpopulations,thuspreventinganysignificantbiasinthetrials.
Second, the proportion of patients with BCLC A and B disease included infirst-line therapy (23%) was similar to the populations… 
2013
2013
A randomized, double-blind, multicenter phase 3 study of brivanib versus placebo as adjuvant therapy to trans-arterial chemoembolization in patients with unresectable hepatocellular carcinoma…
The 7th Annual Conference of the International Liver Cancer Association (ILCA), Washington, D.C., USA, 13-15 September, 2013 
2013
2013
Two-Drug Combo in KRAS Wild-Type CRC Worsened Quality of Life
The two drug combination of cetuximab plus brivanib alaninate worsened quality of life and did not improve overall survival in… 
2012
2012
Synthesis of antitumor drug brivanib
Objective: To synthesize brivanib,a novel antitumor drug,and optimize the preparing process.Methods: Brivanib with good yield was… 
2011
2011
Intravenously and Orally in Healthy Participants Lack of Effect of Brivanib on the Pharmacokinetics of Midazolam , a CYP 3 A 4 Substrate , Administered
http://jcp.sagepub.com/content/early/2011/06/09/0091270011407495 The online version of this article can be found at: DOI: 10.1177… 
2010
2010
Optimal assessment of treatment benefit with targeted agents for hepatocellular carcinoma (HCC): An analysis of brivanib phase II data.
4096 Background: Traditional oncology imaging criteria for response and progression have fallen short in assessing treatment… 
2010
2010
Characterization of brivanib pharmacokinetics and exposure-response (E-R): Relationship of fatigue in patients with advanced and metastatic solid tumors.
3095 Background: Brivanib alaninate is the L-alanine ester prodrug of brivanib, an oral selective dual inhibitor of vascular… 
2008
2008
Gateways to clinical trials.
Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)